Coronavirus Disease 2019 Outcomes Among Recipients of Anti-CD20 Monoclonal Antibodies for Immune-Mediated Diseases: A Comparative Cohort Study.
Naomi J PatelKristin M D'SilvaTiffany Y-T HsuMichael DiIorioXiaoqing FuClaire CookLauren PriscoLily MartinKathleen M M VanniAlessandra ZaccardelliYuqing ZhangJeffrey A SparksZachary Scott WallacePublished in: ACR open rheumatology (2021)
Patients who received anti-CD20 monoclonal antibodies for immune-mediated diseases prior to COVID-19 had higher mortality following COVID-19 than matched comparators, highlighting the urgent need to mitigate excess risks in recipients of anti-CD20 monoclonal antibodies during the ongoing pandemic.